About Agitated Solutions
Agitated Solutions makes tools for clinicians who use sound waves to examine the heart. Its products create and deliver tiny bubbles that make blood flow easier to see, then help clinicians interpret images. The portfolio combines an ultrasound imaging device, an experimental contrast agent and software for assessing abnormal blood flow through the heart.
The Minnesota company is led by co-founder and chief executive Morgan Evans, a medical technology entrepreneur and investor. Her earlier work included corporate development and acquisitions at Medtronic and engineering at Autonomic Technologies. Co-founder and chief medical officer Micah Eimer practices general cardiology and serves as associate chief medical officer at Northwestern Medicine.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 24, 2025 | Oct 22, 2025amended Oct 20, 2026 | $6,385,126of $13.8M target | 53 | $120K | Equity, Options, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| Apr 12, 2022 | Apr 15, 2022 | $1,175,009of $3.5M target | 15 | $78,334 | EquityRule 506(c) | Form D ↗ |
| Mar 18, 2022 | Mar 18, 2022 | $1,574,982fully sold | 24 | $65,624 | EquityRule 506(c) | Form D ↗ |
| Mar 5, 2021 | Mar 11, 2021 | $80,000of $1.3M target | 2 | $40,000 | Debt, Securities on exerciseRule 506(c) | Form D ↗ |
| Total, four offerings | $9,215,117 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Rounds announced by Agitated Solutions
What the company said publicly about its funding. Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
| Announced | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Dec 16, 2025 | Series B | Undisclosed | W. L. Gore & Associates; Engage Venture Partners; individual investors | Company announcement ↗ |
Why Investors Backed Agitated Solutions
Agitated Solutions is building a cardiac ultrasound platform around controlled microbubbles. The investor case combines a commercial device in Canada and Europe, a Phase III U.S. program and software for shunt detection. A medical-device backer is funding clinical work and commercialization.
The problem it targets
Cardiac bubble studies usually require one clinician to mix and inject saline while another captures ultrasound images. The manual process can add up to 25 minutes and produces bubbles with inconsistent size and duration. Poor images can lead to missed diagnoses, inaccurate results or repeat studies. Agitated Solutions also sees a safety risk when preparation and image quality vary.
What the product does
Orbis attaches to a prefilled saline syringe and automatically creates small, uniform bubbles that remain visible longer. The single-use device lets one sonographer deliver the bubbles while capturing images. ASI-02 shows blood crossing abnormally from the heart’s right side to its left. Two AI-enabled software products are being developed to improve images and measure that flow. The company also plans Orbis variants for orthopedics and interventional radiology. AS-O2-001 delivers oxygen bubbles into a large vein as a less invasive respiratory-support option.
Progress so far
In April 2024, Health Canada licensed Orbis, and its first clinical use followed at Toronto General Hospital. The FDA cleared ASI-02 for a Phase III trial in April 2025 and granted Fast Track designation that October. The first ENHANCE participant enrolled at Northwestern University in November 2025. Orbis received a CE Mark in April 2026, allowing sales in the European Union. Evans was also named to three business and cardiovascular leadership lists.
Who backs it
W. L. Gore & Associates’ venture arm joined the Series B syndicate with Engage Venture Partners and individual investors. The financing supports the ENHANCE trial, shunt-detection software and commercial preparation. Gore’s health care venture lead tied its participation to diagnostic accuracy and patient outcomes. Gore also expects to contribute medical technology experience during clinical and commercial development.
How the market is moving
More than four million bubble studies are performed each year in the United States. The tests are standard care for detecting abnormal paths that let blood cross between the heart’s sides. Such paths can contribute to strokes with no known cause. Patent foramen ovale, an opening between the heart chambers, affects roughly 25% to 30% of adults. Together, these figures suggest an established procedure base for the company’s products.
We wrote this summary from public statements by Agitated Solutions and its investors. It is not investment advice.
Agitated Solutions in the News
Leadership Team
Executive officers and directors listed on Agitated Solutions's Form D filed Oct 20, 2026.
Earlier filings also listed Robert Kukuljan (secretary, last listed Apr 2022), Micah Eimer (director, last listed Apr 2022) and Morgan Clyburn (president and director, last listed Mar 2021).
Sources
- SECAGITATED SOLUTIONS, INC. Form D, filed Oct 22, 2025
- SECAGITATED SOLUTIONS, INC. filing history
- CompanyAgitated Solutions About Us
- CompanyAgitated Solutions Privacy Policy
- CompanyAgitated Solutions press releases
- CompanyMorgan Evans recognition announcement
- CompanyOrbis Health Canada announcement
- CompanyOrbis Canada product site
- PressENHANCE trial announcement
- ResearchSBIR company portfolio